Dialysability of gadoteric acid in patients with end-stage renal disease undergoing hemodialysis

Investigative Radiology

Volumn 49, Issue 8, 2014, Pages 505-508

  Gheuens, Eric ^a   Daelemans, Ronald ^a   Mesens, Sofie ^b  

^a Stuivenberg General Hospital   (Belgium)

^b SGS LSS Clinical Pharmacology Unit   (Belgium)

Author keywords

dialysability; ESRD; gadoteric acid; hemodialysis; safety

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM; GADOTERIC ACID; GADOLINIUM 1,4,7,10-TETRAAZACYCLODODECANE-N,N',N'',N'''-TETRAACETATE; HETEROCYCLIC COMPOUND; ORGANOMETALLIC COMPOUND;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); DRUG CLEARANCE; DRUG DIALYSABILITY; DRUG ELIMINATION; END STAGE RENAL DISEASE; FEMALE; HEMODIALYSIS; HUMAN; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; VASCULAR ACCESS; BIOAVAILABILITY; BLOOD; CLINICAL TRIAL; DIAGNOSTIC USE; EXTRAVASATION OF DIAGNOSTIC AND THERAPEUTIC MATERIALS; KIDNEY; KIDNEY FAILURE, CHRONIC; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; PATIENT SAFETY; RENAL REPLACEMENT THERAPY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; BIOLOGICAL AVAILABILITY; CONTRAST MEDIA; EXTRAVASATION OF DIAGNOSTIC AND THERAPEUTIC MATERIALS; FEMALE; HETEROCYCLIC COMPOUNDS; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PATIENT SAFETY; RENAL DIALYSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84904044572     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0000000000000045     Document Type: Article

References (20)

1. Deray G, Rouviere O, Bacigalupo L, et al. Safety of meglumine gadoterate (Gd-DOTA)Yenhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study). Eur Radiol. 2001;23:1250Y1259.
2. Amet S, Launay-Vacher V, Clement O, et al. Incidence of nephrogenic systemic fibrosis in patients undergoing dialysis after contrast-enhanced magnetic resonance imaging with gadolinium-based contrast agents: the Prospective Fibrose Nephrogenique Systemique Study. Invest Radiol. 2014;49:109Y115.
3. Abu-Alfa AK. Nephrogenic systemic fibrosis and gadolinium-based contrast agents. Adv Chronic Kidney Dis. 2011;18:188Y198.
4. Chachuat A, Molinier P, Bonnemain B, et al. Pharmacokinetics and tolerance of Gd-DOTA (DOTAREM) in healthy volunteers and in patients with chronic renal failure. Eur Radiol. 1992;2:326Y329.
5. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol. 1998;5:491Y502.
6. Saitoh T, Hayasaka K, Tanaka Y, et al. Dialysability of gadodiamide in hemodialysis patients. Radiat Med. 2006;24:445Y451.
7. Okada S, Katagiri K, Kumazaki T, et al. Safety of gadolinium contrast agents in hemodialysis patients. Acta Radiol. 2001;42:339Y341.
8. Ueda J, Furukawa T, Yamamoto T, et al. Permeability of gadolinium-DTPA through two types of hemodialysis membrane. Invest Radiol. 1998;33:734Y737.
9. Tombach B, Bremer C, Reimer P, et al. Using highly concentrated gadobutrol as an MR contrast agent in patients also requiring hemodialysis: safety and dialysability. Am J Roentgenol. 2002;178:105Y109.
10. Thomsen HS, Morcos SK, Almén T, et al. Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol. 2013;23:307Y318.
11. Morcos SK, Thomsen HS,Webb JAW. Dialysis and contrast media. Eur Radiol. 2007;12:3026Y3030.
12. Ersoy H, Rybicki FJ. Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis. J Magn Reson Imaging. 2007;26:1190Y1197.
13. Okada S, Inoue K, Kijima T, et al. Effect of the surface potential of the hemodialysis membrane and the electrical charge of the gadolinium contrast medium on dializability. J Nippon Med Sch. 2003;70:12Y15.
14. Haustein J, Schuhmann-Giampieri G. Elimination of Gd-DTPA by means of hemodialysis. Eur J Radiol. 1990;11:221Y229.
15. Aime S, Caravan P. Biodistribution of gadolinium-based contrast agents, including gadolinium deposition. J Magn Reson Imaging. 2009;30:1259Y1267.
16. Abu-Alfa A. The impact of NSF on the care of patients with kidney disease. J Am Coll Radiol. 2008;5:45Y52.
17. Van Wagoner M, Worah D. Gadodiamide injection: first human experience with the nonionic magnetic resonance imaging enhancement agent. Invest Radiol. 1993;28:S44YS48.
18. Silberzweig JI, Chung M. Removal of gadolinium by dialysis: review of different strategies and techniques. J Magn Reson Imaging. 2009;30:1347Y1349.
19. Fretellier N, Idee JM, Dencausse A, et al. Comparative in vivo dissociation of gadolinium chelates in renally impaired rats: a relaxometry study. Invest Radiol. 2011;46:292Y300.
20. Idée JM, Port M, Medina C, et al. Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review. Toxicology. 2008;248:77Y88.